Tumor Imaging Core

项目概要_核心C 核心C临床前肿瘤成像将为所有PPG研究者提供设计和 执行所需的成像实验，以满足每个项目的目标。核心人员将：1）协助 设计和执行成像实验; 2）根据需要存储，处理和分配所有需要的组织 用于下游分析，或用于其他项目; 3）协助或直接执行所有动物成像实验 需要; 4）协助或直接执行所有动物和成像数据分析和解释;以及5）促进 数据的归档和检索。将告知研究者核心C能力的全部潜力，以确保 实验设计充分利用了现有的服务。可用的临床前肿瘤成像功能包括 单光子发射计算机断层扫描结合X射线CT（SPECT-CT）进行全身成像， 活体显微镜（IVM）和静态显微镜成像。我们描述的每种成像方式都很好- 适合于专注于抗体靶向和加工的特定方面。多种成像方法 核心C提供的信息将相互补充和确认，并将提供更完整的分析， 在体内以多个水平靶向、递送和加工。获得的数据将有助于：1）验证AnnA 1 通过使用基于组织化学和荧光的测定法检查组织切片来表达; 2）定义和 使用动态全身成像随时间定量hAnnA 1抗体的肿瘤靶向;和3） 通过动态免疫分析评价和定量hAnnA 1靶向免疫复合物和缀合物的EC加工 新型人类肿瘤模型中的IVM。核心C服务将帮助回答有关AnnA 1分销的关键问题 在人体组织中，肿瘤如何在体内处理特异性探针，以及小窝如何在肿瘤中发挥作用 血管内皮来自临床前图像分析的数据将用于评估药物的有效性， 在项目1和2中用于开发的成像剂，以及在项目3中的最终临床效用。

PROJECT SUMMARY_CORE C Core C Preclinical Tumor Imaging will provide services and expertise to all PPG investigators in designing and executing imaging experiments required to meet the objectives of each project. Core personnel will: 1) assist with design and execute imaging experiments; 2) store, process, and distribute as needed, all tissues required for downstream analysis, or use in other projects; 3) assist or directly perform all animal imaging experiments needed; 4) assist or directly perform all animal and imaging data analyses and interpretation; and 5) facilitate archiving and retrieval of data. Investigators will be advised of the full potential of Core C capabilities to ensure that experimental designs fully utilize available services. Preclinical tumor imaging capabilities available include Single Photon Emission Computed Tomography combined with X-ray CT (SPECT-CT) for whole-body imaging, intravital microscopy (IVM) and static microscopy imaging. Each of our imaging modalities described is well- suited to focus on a specific aspect of antibody targeting and processing. The multiple imaging approaches provided by Core C will complement and confirm one another, and will provide a more complete analysis of targeting, delivery and processing in vivo at multiple levels. Data acquired will assist in: 1) validating AnnA1 expression by examining tissue sections using histochemical and fluorescence based assays; 2) defining and quantifying tumor targeting by hAnnA1 antibodies over time using dynamic whole-body imaging; and 3) evaluating and quantifying EC processing of hAnnA1 targeted immunocomplexes and conjugates via dynamic IVM in novel human tumor models. Core C services will help answer key questions on the distribution of AnnA1 in human tissues, on how tumors process specific probes in vivo, and how caveolae function in the tumor vascular endothelium. Data from preclinical image analysis will be used to assess the effectiveness of drugs and imaging agents for development in Projects 1 and 2, and eventual clinical utility in Project 3.